Financials in GBp. Standardized financial statements.
A compact view of how Renalytix Plc turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue? | £3.00M | £2.29M | £3.40M | £2.97M | £1.49M | £0 | £0 | £0 |
| Revenue Growth? | +31.1% | -32.7% | +14.6% | +99.2% | 0.0% | 0.0% | 0.0% | 0.0% |
| Cost of Revenue? | £1.80M | £2.13M | £2.70M | £2.05M | £804,000 | £74,000 | £30,994 | £0 |
| Gross Profit? | £1.20M | £156,000 | £701,000 | £918,000 | £687,000 | -£74,000 | -£30,994 | £0 |
| Gross Margin? | +40.0% | +6.8% | +20.6% | +30.9% | +46.1% | 0.0% | 0.0% | 0.0% |
| Operating Expenses? | £18.40M | £29.76M | £43.06M | £58.29M | £33.30M | £11.08M | £6.54M | £418,000 |
| Operating Income? | -£17.20M | -£29.61M | -£42.35M | -£53.18M | -£31.92M | -£11.08M | -£6.54M | -£418,000 |
| EBITDA? | -£21.30M | -£28.52M | -£41.71M | -£52.69M | -£32.69M | -£11.08M | -£5.37M | -£418,000 |
| Income Before Tax | -£21.80M | -£33.45M | -£45.60M | -£45.25M | -£35.34M | -£10.61M | -£6.52M | -£418,000 |
| Income Tax Expense | -£1.40M | £4,000 | £2,000 | £25,000 | -£4.78M | £0 | £0 | £0 |
| Net Income? | -£20.40M | -£33.46M | -£45.61M | -£45.28M | -£34.73M | -£9.84M | -£42.30M | -£1.25M |
| EPS? | £-0.21 | £-0.31 | £-0.55 | £-0.62 | £-0.49 | £-0.17 | £-0.99 | £-0.03 |
| Diluted EPS? | £-0.21 | £-0.31 | £-0.55 | £-0.67 | £-0.43 | £-0.17 | £-0.99 | £-0.03 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality